RNA interference as a natural antiviral to mosquito vectored diseases

sharon sanders · Aug 2, 2006

RNA interference acts as a natural antiviral response to O'nyong-nyong virus (Alphavirus; Togaviridae) infection of Anopheles gambiae
Kimberly M. Keene, Brian D. Foy, Irma Sanchez-Vargas, Barry J. Beaty, Carol D. Blair, and Ken E. Olson *
Arthropod-Borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523
Contributed by Barry J. Beaty, October 4, 2004

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Abstract [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]

Top

Abstract

Materials and Methods

Results

Discussion

References
[/SIZE]</TH></TR></TBODY></TABLE>

RNA interference (RNAi) is triggered in eukaryotic organisms by double-stranded RNA (dsRNA), and it destroys any mRNA that has sequence identity with the dsRNA trigger. The RNAi pathway in Anopheles gambiae can be silenced by transfecting cells with dsRNA derived from exon sequence of the A. gambiae Argonaute2 (AgAgo2) gene. We hypothesized that RNAi may also act as an antagonist to alphavirus replication in A. gambiae because RNA viruses form dsRNA during replication. Silencing AgAgo2 expression would make A. gambiae mosquitoes more permissive to virus infection. To determine whether RNAi conditions the vector competence of A. gambiae for O'nyong-nyong virus (ONNV), we engineered a genetically modified ONNV that expresses enhanced GFP (eGFP) as a marker. After intrathoracic injection, ONNV-eGFP slowly spread to other A. gambiae tissues over a 9-day incubation period. Mosquitoes were then coinjected with virus and either control

$beta.gif$

-galactosidase dsRNA (ds

$beta.gif$

gal; note that "ds" is used as a prefix to indicate the dsRNA derived from a given gene throughout) or ONNV dsnsP3. Treatment with dsnsP3 inhibited virus spread significantly, as determined by eGFP expression patterns. ONNV-eGFP titers from mosquitoes coinjected with dsnsP3 were significantly lower at 3 and 6 days after injection than in mosquitoes coinjected with ds

$beta.gif$

gal. Mosquitoes were then coinjected with ONNV-eGFP and dsAgAgo2. Mosquitoes coinjected with virus and AgAgo2 dsRNA displayed widespread eGFP expression and virus titers 16-fold higher than ds

$beta.gif$

gal controls after 3 or 6 days after injection. These observations provide direct evidence that RNAi is an antagonist of ONNV replication in A. gambiae, and they suggest that the innate immune response conditions vector competence. 

[SIZE=-1]innate immunity | mosquito | vector competence[/SIZE]
<HR align=center width="50%" noShade SIZE=1>Arboviruses (arthropod-borne viruses) continue to impact human and animal health worldwide. Mosquito-borne arboviruses replicate and disseminate within susceptible vector tissues before transmission to vertebrate hosts. We know little about how mosquitoes cope with arbovirus infections. However, we expect that mosquitoes have defense mechanisms to counteract or modulate arbovirus infections that could impair host functions. RNA interference (RNAi) may be an important pathway that mosquitoes use to modulate arbovirus replication (1). 
RNAi is a potent intracellular response activated by double-stranded RNA (dsRNA) and results in a reduced steady-state level of specific RNA molecules with sequence similarity to the dsRNA (2, 3). The mechanism of RNAi has been studied in some detail in Drosophila melanogaster. In fruit flies, the RNase III enzyme Dicer is responsible for digesting dsRNA into 21- to 23-bp small interfering RNAs (siRNAs). The siRNAs are then unwound into single-stranded siRNAs in an ATP-dependent step and incorporated into an enzyme complex termed the RNA-induced silencing complex (RISC). The single-stranded siRNAs guide RISC to the target mRNA, and the complex cleaves the message or inhibits its translation (4). An essential component of RISC is Argonaute2 (AGO2), a member of the Argonaute family of proteins. AGO2 has been coimmunoprecipitated with Dicer from Dicer-transfected Drosophila S2 cells (5). A proposed interaction between AGO2 and Dicer2 facilitates the incorporation of siRNAs into RISC, which can target cognate mRNAs for destruction (5, 6). 
There are several reasons to suspect that RNAi is an antagonist of arbovirus replication in mosquitoes. First, the RNAi-like posttranscriptional gene silencing (PTGS) pathway in plants is a potent antiviral response triggered by dsRNA generated by some plant viruses (7). Second, many plant RNA viruses encode suppressors of PTGS, supporting the observations that PTGS acts as a viral defense system (8). For example, the tombusvirus p19 protein suppresses PTGS in plants by binding siRNAs produced after virus infection (9). Third, Li et al. (10) demonstrated that the B2 gene of the insect nodavirus, flock house virus (FHV), can suppress PTGS activity in plants and RNAi in Drosophila S2 cells, emphasizing that an evolutionarily conserved RNAi pathway plays a natural antiviral role. Also, this research group demonstrated that vaccinia and human influenza A, B, and C viruses each encode a protein that suppresses RNAi in mammalian and insect cells (11). 
Studies have shown that RNAi is active in anopheline and culicine mosquitoes (1, 12?19). Recently, Hoa et al. (20) demonstrated that expression of Dicer2, AGO2, and AGO3 proteins are essential for RNAi activity in Anopheles gambiae Sua1B cells. Transient expression of luciferase in the Sua1B cell line was silenced

$ap.gif$

4,000-fold after transfection with dsRNA derived from the luciferase reporter gene. Pretreatment of the cells with dsRNA derived from cDNA sequence of A. gambiae dcr2 (AgDcr2), A. gambiae Ago2 (AgAgo2), or AgAgo3 consistently yielded recovery of luciferase activity, demonstrating that RNAi can be used to silence genes involved in its own pathway and implying that these genes have important roles in RNAi within mosquito cells. The recovery phenomenon was not observed when the cells were treated with

$beta.gif$

-galactosidase (

$beta.gif$

-gal) dsRNA (ds

$beta.gif$

gal; note that "ds" is used as a prefix to indicate the dsRNA derived from a given gene throughout), or dsAgAgo1, dsAgAgo4, and dsAgAgo5 (20). 
A logical progression from these studies would be to determine whether RNAi can act as an antagonist to arbovirus replication in A. gambiae. However, anopheline mosquitoes transmit few arboviruses. An exception is O'nyong-nyong virus (ONNV) (Togaviridae; Alphavirus), which is the etiological agent of a large outbreak of human disease in East Africa from 1959?1962 (21?23) and again in 1996 (24). In epidemics, Anopheles spp. are almost certainly the vectors. Wild-caught Anopheles funestus and A. gambiae mosquitoes held alive for up to 20 days after capture have been found to be infected with ONNV (21). 
ONNV is a small, enveloped RNA virus that replicates exclusively in the cytoplasm of infected cells (25). The genome is a positive-sense, single-stranded, nonsegmented RNA of

$ap.gif$

11.7 kb (25, 26). The 5' two-thirds of the alphavirus genome is translated to form polyproteins that are posttranslationally processed into nsP1?nsP4 proteins to form replicase complexes that synthesize positive or negative RNAs (25, 27). Replication of alphavirus RNA occurs at intracellular membranes in infected cells and leads to formation of dsRNA forms called replicative intermediates (28). The subgenomic (26S) mRNA, colinear with the 3' one-third of the genome, is translated into a structural polyprotein from which capsid, the envelope glycoproteins (E1 and E2), and two smaller polypeptides (E3 and 6K) are produced as cleavage products during glycoprotein processing. Alphavirus RNA genomes are readily manipulated as full-length cDNA infectious clones, and recombinant double subgenomic ONNV has been generated that expresses enhanced GFP (eGFP) as a marker of infection (29). 
In this article, we describe the replication of a recombinant ONNV-eGFP after intrathoracic injection into A. gambiae. When this virus was coinjected with dsRNA derived from the viral genome, virus replication in the mosquito was compromised significantly. In contrast, mosquitoes coinjected with ONN-eGFP and dsRNA derived from AgAgo2 were more permissive to virus replication and dissemination. These experiments demonstrate that RNAi acts as an antiviral response to ONNV-eGFP infections in A. gambiae. 

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Materials and Methods [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]

Top

Abstract

Materials and Methods

Results

Discussion

References
[/SIZE]</TH></TR></TBODY></TABLE>
Cell Lines and Virus Production and Generation of ONNV-eGFP. The infectious cDNA clone, pONN.30a, derived from the Uganda SG-650 strain of ONNV was provided by Ann Powers (Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, CO). The infectious clone was further modified to a recombinant double subgenomic infectious clone expressing eGFP (p5'dsONNic-Foy/eGFP, but for simplicity, it is referred to here as ONNV-eGFP), constructed essentially as described (30) and linearized to form a template for in vitro transcription by using T7 polymerase. RNA from the transcription reaction was electroporated into BHK-21 cells. At 36 h later, the supernatant containing virus was collected, and the virus titer was determined by plaque assay. C6/36 cells (Aedes albopictus) were then infected at an multiplicity of infection of 0.01, and 60 h later, supernatant containing the virus was collected and titrated. The virus stock contained 2.1 [FONT=arial,helvetica]x[/FONT] 107 plaque-forming units (pfu)/ml. 
Mosquitoes and Intrathoracic Inoculation of Virus and/or dsRNAs. A. gambiae (G3 strain) were reared on an artificial diet of ground fish food at 30?C with a 14 h light/10 h dark photoperiod. Adult female A. gambiae (2?4 days after emergence) were injected with 0.5 ?l of inoculum. For viral characterization studies, viral stock was diluted to 1 [FONT=arial,helvetica]x[/FONT] 107 pfu/ml before injection, and thus, each mosquito received

$ap.gif$

5 [FONT=arial,helvetica]x[/FONT] 103 pfu of virus. For coinjections of virus and dsRNA, dsRNA was diluted to a concentration of 1 ?g/?l in PBS and mixed 1:1 (vol/vol) with the undiluted stock (2.1 [FONT=arial,helvetica]x[/FONT] 107 pfu/ml). Thus, each mosquito was inoculated with

$ap.gif$

5.3 [FONT=arial,helvetica]x[/FONT] 103 pfu of virus and 250 ng of dsRNA. 
Characterization of ONNV Infection in A. gambiae Mosquitoes. After inoculation, A. gambiae adult female mosquitoes were assayed at 3, 6, and 9 days postinjection (dpi). Mosquitoes were killed by brief submersion in 70% ethanol, washed in saline, and assayed initially for eGFP expression under UV light. The heads were then removed, squashed on glass slides, fixed in acetone, and assayed for viral antigen by immunofluorescence assay using an mAb (30.11a) that was developed against Sindbis virus E2 protein but cross-reacts with ONNV E2 protein. The thorax and abdomen of each mosquito were frozen individually at ?70?C and later titrated by plaque assay (described below). 
Generation of dsRNA. cDNAs were generated from total mosquito RNA [extracted from fourth-instar larvae by using the RNeasy kit (Qiagen, Valencia, CA)] by RT-PCR using an oligo(dT) primer. Oligonucleotide primers were designed to amplify

$ap.gif$

500-bp regions of A. gambiae Ago1?5 cDNA, and they incorporated T7 promoter sequences at the 5' ends (Table 1). Control

$ap.gif$

500-bp cDNA templates were generated by PCR using primers specific for portions of the Escherichia coli

$beta.gif$

-gal cDNA clone and for the nsP3 gene from ONNV-eGFP. To generate dsRNA, PCR products were purified by gel extraction and used as templates for in vitro transcription using the MegaScript kit (Ambion, Austin, TX), and dsRNAs were purified according to the manufacturer's instructions. The quality of dsRNA was checked by agarose gel electrophoresis and quantified by using a spectrophotometer. 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>View this table:
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Table 1. Primer pairs for amplification of dsRNA template from A. gambiae
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>
Determination of Virus Titer. Mosquitoes were triturated in 270 ?l of DMEM by using a mortar and pestle, and large particulates were pelleted by centrifugation. The supernatant was passed through a 0.22-?m filter and then titrated by standard plaque assay by using Vero cells (31). We counted pfu, and the data were log10 transformed. Differences in viral titers were first analyzed by ANOVA, and the titers in the treatment groups were found to be significantly different (P < 0.01). Pairwise t tests were then performed. Highly significant differences (P < 0.0001) between treatments groups and controls are marked with two asterisks, and significant differences (P < 0.05) are marked with a single asterisk. 
Northern Blot Analysis. Total RNA was isolated at 2?3 dpi from 50?60 mosquitoes for each treatment group by using the guanidine isothiocyanate/phenol?chloroform method of extraction. mRNA was purified from total RNA by using the MicroPoly(A) Purist kit (Ambion). We separated 10 ?g of mRNA on a 1% agarose-formaldehyde gel and transferred to a BrightStar Plus nylon membrane (Ambion). The blots were hybridized with 32P-labeled probe complementary to the ONNV E2 gene (Fig. 1B) or AgAgo2 (Fig. 4). The blots were then washed at 68?C, and radioactivity was detected by using a Storm PhosphoImager (Molecular Dynamics, Amersham Biosciences). 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (44K):
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Fig. 1. Design and characterization of recombinant ONNV-eGFP. (A) p5'dsONNVic/Foy contains a full-length cDNA of the ONNV genome with a second subgenomic promoter inserted 3' of the original subgenomic promoter. eGFP was cloned into the MCS and is transcribed under control of the first subgenomic promoter. (B) Characterization of viral transcripts of ONNV after injection into adult female A. gambiae. Lanes 1 and 2 show the ONNV-eGFP transcript profile at 48 and 72 h after infection, respectively. The blot was hybridized by using a radiolabeled ONNV E2 gene as probe, and it shows the production of the full-length genomic and two subgenomic transcripts. (C) eGFP expression at 9 dpi occurs throughout the body.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>

<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (51K):
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Fig. 4. Northern blot analysis of AgAgo2 mRNA after injection of mosquitoes with ONNV-eGFP, dsRNA, or dsRNA and ONNV-eGFP. Injection of dsAgAgo2 results in the reduction of Ago2 transcript levels. Mosquitoes injected with dsAgAgo2 and virus showed partial recovery of the Ago2 mRNA accumulation. (Upper) Lane 1, mock injected; lane 2, ds

$beta.gif$

gal at 3 dpi; lane 3, dsAgAgo2 at 3 dpi; lane 4, dsAgAgo2 + ONNV-eGFP 3 at dpi; lane 5, ONNV-eGFP 2 dpi; and lane 6, ONNV-eGFP 3 dpi. (Lower) Ethidium bromide stain of Northern blot showing ribosomal RNA in each lane and verifying that equivalent amounts of total RNA were added to each lane.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Results [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]

Top

Abstract

Materials and Methods

Results

Discussion

References
[/SIZE]</TH></TR></TBODY></TABLE>
Construction and in Vivo Characterization of Intrathoracically Injected ONNV-eGFP. The pONNV.30a infectious clone was engineered to contain a duplicated subgenomic promoter, 3' to the original subgenomic promoter (Fig. 1 A). eGFP was inserted immediately downstream of the first subgenomic promoter into a multiple cloning site, generating ONNV-eGFP plasmid. Recombinant virus was produced from this plasmid and injected into A. gambiae mosquitoes. The three RNA species predicted from virus transcription were not detectable by Northern blotting of mosquito RNA after 48 h, but they were apparent after 72 h (Fig. 1B), indicating a relatively slow rate of viral replication in A. gambiae tissue. Viral titers in the mosquito at 3 dpi were lower than the input titer by >1.5 log pfu (Table 2), but they then slowly increased over a 9-day incubation period. Virus was detected in the head tissues of individual mosquitoes both by eGFP expression and by immunofluorescence analysis of the E1 glycoprotein (Table 2). The data indicate that these methods of detection are equivalent and that eGFP serves as a readily detectable marker of infection during this time period. eGFP expression in injected mosquitoes at 9 dpi revealed temporal and spatial infection patterns of the virus (Fig. 1C). Virus typically infected nervous, muscle, and fat body tissues. When ONNV-eGFP dissemination to the head occurred, ommatidia and cells in the maxillary palps, antennae, and in the mouth parts expressed eGFP, but the marker was not apparent in salivary glands (data not shown). In the abdomen, eGFP was most often sporadically associated with circular muscle fibers wrapping the alimentary canal and with fat body. 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>View this table:
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Table 2. Dissemination of 5' dsONNic-Foy/eGFP after injection in A. gambiae
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>
Inhibition of Virus Replication After Coinjection with ONNV and dsRNA Targeting ONNV nsP3 Gene Sequence. Initially, we tested whether the RNAi pathway in A. gambiae could inhibit virus replication and dissemination by introduction of nsP3 gene dsRNA (dsnsP3) to target the virus genome. Mosquitoes were coinjected with 5.3 [FONT=arial,helvetica]x[/FONT] 103 pfu of virus and 250 ng of ONNV dsnsP3. Mosquitoes were also coinjected with the same dose of ONNV-eGFP virus and ds

$beta.gif$

gal. Primers for generating dsRNAs are given in Table 1. In mosquitoes receiving dsnsP3, eGFP was usually restricted to thoracic tissue surrounding the site of injection (Fig. 2A). Mosquitoes coinjected with virus and ds

$beta.gif$

gal control usually had more extensive expression of eGFP in the thorax (Fig. 2B). At 3 dpi, 86% (n = 58) of mosquitoes receiving ds

$beta.gif$

gal expressed eGFP in thoracic tissues, but only 38% (n = 52) expressed eGFP in thoracic tissues when dsnsP3 was coinjected (Table 3). At 3 dpi, 23% (n = 52) of mosquitoes receiving dsnsP3 showed eGFP expression in head tissues and none of the same mosquitoes had eGFP in abdominal tissue (Table 3). In contrast, 34% (n = 58) of mosquitoes receiving ds

$beta.gif$

gal had eGFP expression in their head and abdominal tissues (Table 3). At 6 dpi, 57% (n = 53) of mosquitoes injected with ds

$beta.gif$

gal had eGFP in their head and abdominal tissues; however, eGFP could only be seen in 36% of the head tissue and 16% of the abdominal tissue (n = 52) of mosquitoes coinjected with virus and dsnsP3 (Table 3). 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (155K):
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Fig. 2. eGFP expression at 3 dpi in mosquitoes coinjected with dsRNAs and ONNV-eGFP. (A) Coinjection of ONNV-eGFP and dsnsP3. (B) Coinjection of ONNV-eGFP and ds

$beta.gif$

gal. (C) Coinjection of ONNV-eGFP and dsAgAgo2. Mosquitoes injected with dsnsP3 show a dramatic reduction in eGFP expression when compared with ds

$beta.gif$

gal-injected controls, whereas mosquitoes injected with dsAgAgo2 show an increase in eGFP expression over controls.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>

<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>View this table:
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Table 3. Percentage of injected mosquitoes displaying eGFP expression in body tissues after coinjection of ONNV-eGFP and dsnsP3 or dsAgAgo2 at 3 and 6 dpi
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>
To quantitate virus abundance, mosquitoes were triturated and virus titer was determined by plaque assay from these treatment groups. No significant difference in the number of plaques was observed between the mosquitoes injected only with ONNV-eGFP and mosquitoes coinjected with ds

$beta.gif$

gal (P > 0.08). However, mosquitoes coinjected with ONNV-eGFP and dsnsP3 had significantly fewer plaques than those mosquitoes coinjected with ONNV-eGFP and ds

$beta.gif$

gal (P < 0.0001) at both 3 and 6 dpi (Fig. 3). 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (23K):
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Fig. 3. Viral titers of ONNV-eGFP in mosquitoes coinjected with dsRNA homologous to ONNV nsP3 and AgAgo2. Compared with the nonspecific ds

$beta.gif$

gal, mosquitoes coinjected with virus and dsnsP3 had statistically significant decreases in infection at both 3 and 6 dpi (P < 0.0001). Viral titers of ONNV-eGFP increased significantly in mosquitoes at 3 and 6 dpi after coinjection with dsRNAs homologous with AgAgo2 (P < 0.0001 and P = 0.0006 at 3 and 6 dpi, respectively).
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Coinjection of ONNV and dsRNAs Homologous to AgAgo2. We then coinjected mosquitoes with dsAgAgo2 to observe whether silencing of AgAgo2 expression would make mosquitoes more permissive to ONNV. At 3 dpi, these mosquitoes usually displayed dramatic increases in eGFP expression with eGFP detected in tissues in all body segments (Fig. 2C). At 3 dpi, only 34% (n = 58) of mosquitoes treated with ONNV-eGFP and ds

$beta.gif$

gal showed eGFP in their heads and abdomens, but

$ge.gif$

97% (n = 63) of mosquitoes treated with dsAgAgo2 showed eGFP in the same tissues (Table 3). At 6 dpi, 57% (n = 53) of mosquitoes injected with virus and ds

$beta.gif$

gal displayed eGFP in head and abdominal tissues; 100% (n = 36) injected with virus and dsAgAgo2 displayed eGFP in those tissues (Fig. 3). 
We examined mRNA accumulation of AgAgo2 in mosquitoes after injection with dsAgAgo2 to determine whether the dsRNA specifically silenced AgAgo2 mRNA. Injection of nonspecific ds

$beta.gif$

gal failed to silence AgAgo2 mRNA, but injection of dsAgAgo2 silenced accumulation of Ago2 mRNA in mosquitoes (Fig. 5, lane 3). Interestingly, we detected partial recovery of AgAgo2 mRNA when ONNV was coinjected with dsAgAgo2 (Fig. 5, lane 4). AgAgo2 mRNA levels in mosquitoes injected with ONNV alone were similar to noninjected and ds

$beta.gif$

gal-injected controls. 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>

View larger version (27K):
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Fig. 5. Viral titers of ONNV-eGFP in mosquitoes at 3 and 6 dpi after coinjection of dsRNA homologous to AgAgo1, AgAgo3, AgAgo4, and AgAgo5. Compared with the nonspecific ds

$beta.gif$

gal, only mosquitoes coinjected with virus and dsAgAgo3 had statistically significant increases at 3 and 6 dpi (P

$le.gif$

0.0141).
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Finally, virus titers were recovered on the same mosquitoes used for determining the eGFP expression profiles. Mosquitoes treated with dsAgAgo2 had significantly more infectious virus per mosquito at 3 dpi than mosquitoes treated with ds

$beta.gif$

gal (16-fold increase; P < 0.0001, Fig. 4). At 6 dpi, viral titers increased in all tested mosquitoes, but dsAgAgo2-treated mosquitoes still had significantly more virus per mosquito than ds

$beta.gif$

gal-treated controls (P = 0.0006, Fig. 4). 
Coinjection of ONNV and dsRNAs Homologous to AgAgo1, AgAgo3, AgAgo4, and AgAgo5. Mosquitoes were injected with virus and dsRNAs derived from AgAgo1, AgAgo3, AgAgo4, and AgAgo5 (20). These studies were performed to observe whether silencing of other AgAgo genes also could increase mosquito permissiveness to ONNV replication, possibly implicating them in RNAi modulation of ONNV-eGFP replication. At 3 and 6 dpi, mosquitoes coinjected with virus and AgAgo-derived dsRNAs (dsAgAgo1, dsAgAgo3, dsAgAgo4, and dsAgAgo5) usually displayed similar eGFP expression patterns to that seen with the ds

$beta.gif$

gal control mosquitoes (Table 4). The only exception was that mosquitoes injected with dsAgAgo3 consistently had greater dissemination of virus in all tissues than those injected with either ds

$beta.gif$

gal or dsAgAgo1, dsAgAgo4, and dsAgAgo5 (Table 4). These observations were confirmed by virus titration. Virus titers in mosquitoes injected with dsAgAgo3 differed significantly from those mosquitoes injected with ds

$beta.gif$

gal at 3 dpi (P = 0.0067) and at 6 dpi (P = 0.0141) (Fig. 5). Virus titers in mosquitoes injected with dsAgAgo1, dsAgAgo4, and dsAgAgo5 did not differ statistically from those mosquitoes injected with ds

$beta.gif$

gal at 3 and 6 dpi. 


<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>View this table:
[in this window]
[in a new window]
 </TD><TD vAlign=top align=left>Table 4. Percentage of injected mosquitoes displaying eGFP expression in body tissues after coinjection of ONNV-eGFP and dsRNAs from AgAgo1, AgAgo3, AgAgo4, and AgAgo5 at 3 and 6 dpi
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Discussion [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]

Top

Abstract

Materials and Methods

Results

Discussion

References
[/SIZE]</TH></TR></TBODY></TABLE>
In this study, we demonstrated that RNAi can act as an antagonist to arbovirus replication in mosquitoes. We describe an alphavirus transducing system based on ONNV and follow the course of infection after injection of recombinant virus into the A. gambiae hemocoel. After injection into the hemocoel, ONNV-eGFP replicated slowly in A. gambiae. Injection of dsRNA cognate to a portion of the ONNV genome and stimulation of RNAi further slowed ONNV replication in this mosquito species. Injection of dsRNA cognate to AgAgo2, which is a gene known to function in the A. gambiae RNAi pathway (20), silenced RNAi, thereby permitting ONNV-eGFP to replicate and disseminate quickly in mosquitoes. In addition, dsRNA derived from AgAgo3 also made mosquitoes more permissive to ONNV-eGFP replication at 3 and 6 dpi. In contrast, dsRNAs derived from AgAgo1, AgAgo4, and AgAgo5 did not alter virus replication significantly at either 3 or 6 dpi. These data suggest a regulatory role for RNAi in controlling arbovirus infections in mosquitoes. 
The pathogenesis of ONNV in A. gambiae is unusual when compared with typical alphavirus?vector models. When injected into culicine mosquitoes, ONNV, like other alphaviruses (Sindbis virus and Venezuelan equine encephalitis virus), replicates efficiently and rapidly spreads throughout the mosquito (32?34; B.D.F., unpublished data). However, ONNV replication in A. gambiae is relatively slow after intrathoracic injection. ONNV also infects A. gambiae midgut tissues after per os infection, but it has an unusual tropism for the anterior midgut epithelium and is limited in its ability to escape from the alimentary canal (29). A. gambiae may not be the ideal vector for ONNV. A. funestus has been implicated as a potentially better vector of ONNV in Africa (21, 23). It would be interesting to observe whether A. funestus can modulate ONNV-eGFP infection as readily as A. gambiae. 
Our results point to the AGO2, and possibly AGO3, proteins as critical components of a mosquito RNAi pathway involved in the inhibition of alphavirus replication. ONNV replication was affected most by silencing of Ago2, which has been shown to be an important RISC component in Drosophila (5). Northern blot analysis showed that the presence of dsAgAgo2 leads to reduced amounts of AgAgo2 mRNA in vivo, but the analysis also suggests that infection with ONNV stimulates recovery of this transcript accumulation. A possible explanation is that ONNV infection induced transcription of AgAgo2, although there is no supporting evidence for this hypothesis. The other, more likely, explanation is that ONNV encodes a repressor of RNAi in the mosquito, which has been shown with other RNA viruses (8). The ONNV suppressor might counteract the silencing from dsAgAgo2 injection. Transcription of ONNV-eGFP was first detected at 72 h after infection (Fig. 1B), which is when an ONNV suppressor protein may be translated in sufficient quantities to have an effect on RNAi. Even if one or both of these possibilities is correct, it is clear that the injection of dsAgAgo2 has a strong biological effect that resulted in increased ONNV titers in the mosquito that lasted at least 6 days after treatment. 
The Argonaute family comprises a group of proteins, some of which are required for RNAi and others of which have roles in regulating development. We have demonstrated that AgAgo2 and AgAgo3 are involved in RNAi both in cell culture (20) and in mosquitoes. Whereas the Drosophila ortholog of Ago2 has been characterized, Ago3 has not (5, 35). DmAgo1 is required for efficient RNAi in Drosophila, functioning in the pathway after the production of siRNA (36). We hypothesized previously that the function of AgAgo3 may be analogous to that of DmAgo1 (20). The Drosophila paralogues of AgAgo4 and AgAgo5, piwi and aubergine, have known functions in development (35). 
Several innate immune pathways in mosquitoes have been elucidated for defense against bacterial and macroparasite infections (18, 37?40); however, no antiviral mechanisms or pathways have been described. In vertebrate species, there are innate immune mechanisms that recognize and mount responses to dsRNA, including the interferon and protein kinase R pathways, but neither has been detected in the mosquito. The data presented in this article support the idea that RNAi is a mechanism to protect mosquitoes from viral infection. We hypothesize that vector competence for an alphavirus is partly due to the balance struck between the opposing forces of vector and arbovirus evolution. Some alphaviruses may replicate and disseminate so quickly as to avoid induction of an RNAi defense, or they may quickly disseminate from tissues with a strong RNAi response and into mosquito tissues with a weak RNAi response (30, 41, 42). For example, the C. elegans nervous system has been shown to be refractory to silencing of mRNA by RNAi (43). Also, many plant viruses encode suppressors of RNAi that may also be present in alphaviruses (8). Different vector species are also likely to show differences in their RNAi responses. Some mosquitoes may preferentially express negative regulators of RNAi, such as the ERI-1 protein that has been identified in C. elegans (44). Data demonstrating dsRNA effectiveness against myriad targets in A. gambiae (12, 18, 19) may indicate that these mosquitoes generally have a robust RNAi response, which could partly explain why anopholine mosquitoes are such poor vectors of arboviruses. Mosquitoes such as Aedes aegypti readily transmit both alphaviruses (Chikungunya and Sindbis), and flaviviruses (yellow fever and dengue), possibly indicating that these mosquitoes have a weaker RNAi response. In support of this hypothesis, we have observed that ONNV readily disseminates in A. aegypti tissues after injection but that the Sindbis virus MRE16 strain (30), which disseminates very efficiently in all of the culicines that we have injected, could not replicate in A. gambiae tissues (data not shown). 
This study is the first step in understanding how RNAi naturally modulates arboviral infection in the mosquito. An understanding of whether the RNAi response can modulate arboviral infection and dissemination in other vector mosquitoes and by other families of arboviruses would provide a better understanding of how mosquitoes respond to virus infection, and it would possibly provide researchers with information on how to design strategies that enhance mosquito refractoriness to arboviruses. 

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Acknowledgements [/SIZE]</TH></TR></TBODY></TABLE>
We thank Drs. Ann Powers and Aaron Brault (University of California, Davis) for their gift of pONN.30A. We also thank Cynthia Meredith and Sarah VanOtterloo for assistance with mosquito rearing. This work was supported by National Institutes of Health Grants AI-34014, AI-25489, and AI46435. 

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Footnotes [/SIZE]</TH></TR></TBODY></TABLE>
Author contributions: K.M.K., B.D.F., I.S.-V., B.J.B., C.D.B., and K.E.O. designed research; K.M.K., B.D.F., and I.S.-V. performed research; K.M.K., B.D.F., I.S.-V., B.J.B., C.D.B., and K.E.O. analyzed data; and K.M.K., B.D.F., and K.E.O. wrote the paper. 
Abbreviations: RNAi, RNA interference; dsRNA, double-stranded RNA; eGFP, enhanced GFP; dpi, days postinjection;

$beta.gif$

-gal,

$beta.gif$

-galactosidase; ONNV, O'nyong-nyong virus; RISC, RNA-induced silencing complex; AgAgo, Anopheles gambiae Ago; AGO2/3, Argonaute2/3; pfu, plaque-forming units; siRNA, small interfering RNA. 
* To whom correspondence should be addressed. E-mail: kolson@colostate.edu<SCRIPT type=text/javascript></SCRIPT> .
? 2004 by The National Academy of Sciences of the USA

<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>

</TD><TH vAlign=center align=left width="95%">[SIZE=+2] References [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]

Top

Abstract

Materials and Methods

Results

Discussion

References
[/SIZE]</TH></TR></TBODY></TABLE>

<LI value=1>Sanchez-Vargas, I., Travanty, E. A., Keene, K. M., Franz, A. W., Beaty, B. J., Blair, C. D. & Olson, K. E. (2004) Virus Res. 102, 65?74.[CrossRef][ISI][Medline] <LI value=2>Cogoni, C. & Macino, G. (1997) Proc. Natl. Acad. Sci. USA 94, 10233?10238.[Abstract/Free Full Text] <LI value=3>Vaucheret, H., Beclin, C., Elmayan, T., Feuerbach, F., Godon, C., Morel, J. B., Mourrain, P., Palauqui, J. C. & Vernhettes, S. (1998) Plant J. 16, 651?659.[CrossRef][ISI][Medline] <LI value=4>Schwarz, D. S., Hutvagner, G., Haley, B. & Zamore, P. D. (2002) Mol. Cell 10, 537?548.[ISI][Medline] <LI value=5>Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R. & Hannon, G. J. (2001) Science 293, 1146?1150.[Abstract/Free Full Text] <LI value=6>Pham, J. W., Pellino, J. L., Lee, Y. S., Carthew, R. W. & Sontheimer, E. J. (2004) Cell 117, 83?94.[CrossRef][ISI][Medline] <LI value=7>Kasschau, K. D. & Carrington, J. C. (1998) Cell 95, 461?470.[ISI][Medline] <LI value=8>Roth, B. M., Pruss, G. J. & Vance, V. B. (2004) Virus Res. 102, 97?108.[CrossRef][ISI][Medline] <LI value=9>Silhavy, D., Molnar, A., Lucioli, A., Szittya, G., Hornyik, C., Tavazza, M. & Burgyan, J. (2002) EMBO J. 21, 3070?3080.[Abstract/Free Full Text] <LI value=10>Li, H., Li, W. X. & Ding, S. W. (2002) Science 296, 1319?1321.[Abstract/Free Full Text] <LI value=11>Li, W. X., Li, H., Lu, R., Li, F., Dus, M., Atkinson, P., Brydon, E. W., Johnson, K. L., Garcia-Sastre, A., Ball, L. A. et al. (2004) Proc. Natl. Acad. Sci. USA 101, 1350?1355.[Abstract/Free Full Text] <LI value=12>Blandin, S., Moita, L. F., Kocher, T., Wilm, M., Kafatos, F. C. & Levashina, E. A. (2002) EMBO Rep. 3, 852?856.[Abstract/Free Full Text] <LI value=13>Levashina, E. A., Moita, L. F., Blandin, S., Vriend, G., Lagueux, M. & Kafatos, F. C. (2001) Cell 104, 709?718.[CrossRef][ISI][Medline] <LI value=14>Brown, A. E., Crisanti, A. & Catteruccia, F. (2003) J. Exp. Biol. 206, 1817?1823.[Abstract/Free Full Text] <LI value=15>Attardo, G. M., Higgs, S., Klingler, K. A., Vanlandingham, D. L. & Raikhel, A. S. (2003) Proc. Natl. Acad. Sci. USA 100, 13374?13379.[Abstract/Free Full Text] <LI value=16>Adelman, Z. N., Blair, C. D., Carlson, J. O., Beaty, B. J. & Olson, K. E. (2001) Insect Mol. Biol. 10, 265?273.[CrossRef][ISI][Medline] <LI value=17>Adelman, Z. N., Sanchez-Vargas, I., Travanty, E. A., Carlson, J. O., Beaty, B. J., Blair, C. D. & Olson, K. E. (2002) J. Virol. 76, 12925?12933.[Abstract/Free Full Text] <LI value=18>Blandin, S., Shiao, S. H., Moita, L. F., Janse, C. J., Waters, A. P., Kafatos, F. C. & Levashina, E. A. (2004) Cell 116, 661?670.[CrossRef][ISI][Medline] <LI value=19>Osta, M. A., Christophides, G. K. & Kafatos, F. C. (2004) Science 303, 2030?2032.[Abstract/Free Full Text] <LI value=20>Hoa, N. T., Keene, K. M., Olson, K. E. & Zheng, L. (2003) Insect Biochem. Mol. Biol. 33, 949?957.[CrossRef][ISI][Medline] <LI value=21>Corbet, P. S., Williams, M. C. & Gillett, J. D. (1961) Trans. R. Soc. Trop. Med. Hyg. 55, 463?480.[CrossRef][Medline] <LI value=22>Williams, M. C. & Woodall, J. P. (1961) Trans. R. Soc. Trop. Med. Hyg. 55, 135?141.[CrossRef] <LI value=23>Williams, M. C. & Woodall, J. P. (1965) Trans. R. Soc Trop. Med. Hyg. 59, 300?306.[CrossRef][ISI][Medline] <LI value=24>Lanciotti, R. S., Ludwig, M. L., Rwaguma, E. B., Lutwama, J. J., Kram, T. M., Karabatsos, N., Cropp, B. C. & Miller, B. R. (1998) Virology 252, 258?268.[CrossRef][ISI][Medline] <LI value=25>Strauss, J. H. & Strauss, E. G. (1994) Microbiol. Rev. 58, 491?562.[ISI][Medline] <LI value=26>Strauss, E. G., Rice, C. M. & Strauss, J. H. (1984) Virology 133, 92?110.[ISI][Medline] <LI value=27>Sawicki, D. L. & Sawicki, S. G. (1994) Arch. Virol. Suppl. 9, 393?405.[Medline] <LI value=28>Barton, D. J., Sawicki, S. G. & Sawicki, D. L. (1991) J. Virol. 65, 1496?1506.[ISI][Medline] <LI value=29>Brault, A. C., Foy, B. D., Myles, K. M., Higgs, S., Weaver, S. C., Olson, K. E., Miller, B. R. & Powers, A. M. (2004) Mol. Biol., in press. <LI value=30>Foy, B. D., Myles, K. M., Pierro, D. J., Sanchez-Vargas, I., Uhlirova, M., Jindra, M., Beaty, B. J. & Olson, K. E. (2004) Insect Mol. Biol. 13, 89?100.[ISI][Medline] <LI value=31>Myles, K. M., Pierro, D. J. & Olson, K. E. (2003) J. Virol. 77, 8872?8881.[Abstract/Free Full Text] <LI value=32>Bowers, D. F., Abell, B. A. & Brown, D. T. (1995) Virology 212, 1?12.[CrossRef][ISI][Medline] <LI value=33>Weaver, S. C., Scherer, W. F., Cupp, E. W. & Castello, D. A. (1984) Am. J. Trop. Med. Hyg. 33, 953?960.[ISI][Medline] <LI value=34>Shope, R. E. (1985) in Virology, ed. Fields, B. N. (Raven, New York), Vol. 3, pp. 931?951. <LI value=35>Carmell, M. A., Xuan, Z., Zhang, M. Q. & Hannon, G. J. (2002) Genes Dev. 16, 2733?2742.[Free Full Text] <LI value=36>Williams, R. W. & Rubin, G. M. (2002) Proc. Natl. Acad. Sci. USA 99, 6889?6894.[Abstract/Free Full Text] <LI value=37>Lowenberger, C. (2001) Insect Biochem. Mol. Biol. 31, 219?229.[CrossRef][ISI][Medline] <LI value=38>Gorman, M. J. & Paskewitz, S. M. (2001) Insect Biochem. Mol. Biol. 31, 257?262.[CrossRef][ISI][Medline] <LI value=39>Christophides, G. K., Zdobnov, E., Barillas-Mury, C., Birney, E., Blandin, S., Blass, C., Brey, P. T., Collins, F. H., Danielli, A., Dimopoulos, G., et al. (2002) Science 298, 159?165.[Abstract/Free Full Text] <LI value=40>Kumar, S., Christophides, G. K., Cantera, R., Charles, B., Han, Y. S., Meister, S., Dimopoulos, G., Kafatos, F. C. & Barillas-Mury, C. (2003) Proc. Natl. Acad. Sci. USA 100, 14139?14144.[Abstract/Free Full Text] <LI value=41>Scott, T. W. & Burrage, T. G. (1984) Am. J. Trop. Med. Hyg. 33, 961?964.[ISI][Medline] <LI value=42>Weaver, S. C. (1986) Am. J. Trop. Med. Hyg. 35, 624?631.[ISI][Medline] <LI value=43>Kamath, R. S. & Ahringer, J. (2003) Methods 30, 313?221.[CrossRef][ISI][Medline]
Kennedy, S., Wang, D. & Ruvkun, G. (2004) Nature 427, 645?649.[CrossRef][ISI][Medline]

sharon sanders · Aug 2, 2006

Table 1

Table 1

Table 1. Primer pairs for amplification of dsRNA template from A. gambiae

<TABLE border=0><TBODY><TR><TD><TABLE cellSpacing=10 cellPadding=0 width="100%"><TBODY><TR><TD colSpan=3><HR noShade SIZE=1></TD></TR><TR><TD vAlign=bottom align=left>Target gene

<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Forward primer, 5'-3'

<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Reverse primer, 5'-3'

<HR noShade SIZE=1></TD></TR><TR><TD vAlign=top align=left>Ago1 </TD><TD vAlign=top align=left>GCAGGTGTCCCTGTTCAACCT </TD><TD vAlign=top align=left>GGTTTGGCCGTTCTCTAGCTG </TD></TR><TR><TD vAlign=top align=left>Ago2 </TD><TD vAlign=top align=left>GCATGAGCACGCTCAACAAC </TD><TD vAlign=top align=left>GTTCGAGTCGTCGTACAGCA </TD></TR><TR><TD vAlign=top align=left>Ago3 </TD><TD vAlign=top align=left>GTGTGGCATTGACACGTACC </TD><TD vAlign=top align=left>GCTCAGCTGCTGCAGAATGTC </TD></TR><TR><TD vAlign=top align=left>Ago4 </TD><TD vAlign=top align=left>GCGACTTCCTCAACTGCATGA </TD><TD vAlign=top align=left>GTGTTGAGCGGCAGATAGTTG </TD></TR><TR><TD vAlign=top align=left>Ago5 </TD><TD vAlign=top align=left>GACAAGTCGCTCTCGTACGGT </TD><TD vAlign=top align=left>GTCTCGTCGAAGATCACGTTG </TD></TR><TR><TD vAlign=top align=left>ONNV nsp3 </TD><TD vAlign=top align=left>CATGTGGCCAAAACAAACTG </TD><TD vAlign=top align=left>CGAATTTGCGTACATTGGTG </TD></TR><TR><TD vAlign=bottom align=left>

$beta.gif$

-gal

<HR noShade SIZE=1></TD><TD vAlign=bottom align=left>GGTCGCCAGCGGCACCGCGCCTTC

<HR noShade SIZE=1></TD><TD vAlign=bottom align=left>GCCGGTAGCCAGCGCGGATCATCGG
<HR noShade SIZE=1></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>

sharon sanders · Aug 2, 2006

Figure 1

Figure 1

Fig. 1. Design and characterization of recombinant ONNV-eGFP. (A) p5'dsONNVic/Foy contains a full-length cDNA of the ONNV genome with a second subgenomic promoter inserted 3' of the original subgenomic promoter. eGFP was cloned into the MCS and is transcribed under control of the first subgenomic promoter. (B) Characterization of viral transcripts of ONNV after injection into adult female A. gambiae. Lanes 1 and 2 show the ONNV-eGFP transcript profile at 48 and 72 h after infection, respectively. The blot was hybridized by using a radiolabeled ONNV E2 gene as probe, and it shows the production of the full-length genomic and two subgenomic transcripts. (C) eGFP expression at 9 dpi occurs throughout the body.

sharon sanders · Aug 2, 2006

Figure 4

Figure 4

Fig. 4. Northern blot analysis of AgAgo2 mRNA after injection of mosquitoes with ONNV-eGFP, dsRNA, or dsRNA and ONNV-eGFP. Injection of dsAgAgo2 results in the reduction of Ago2 transcript levels. Mosquitoes injected with dsAgAgo2 and virus showed partial recovery of the Ago2 mRNA accumulation. (Upper) Lane 1, mock injected; lane 2, ds

$beta.gif$

gal at 3 dpi; lane 3, dsAgAgo2 at 3 dpi; lane 4, dsAgAgo2 + ONNV-eGFP 3 at dpi; lane 5, ONNV-eGFP 2 dpi; and lane 6, ONNV-eGFP 3 dpi. (Lower) Ethidium bromide stain of Northern blot showing ribosomal RNA in each lane and verifying that equivalent amounts of total RNA were added to each lane.

sharon sanders · Aug 2, 2006

Table 2

Table 2

Table 2. Dissemination of 5' dsONNic-Foy/eGFP after injection in A. gambiae
<TABLE border=0><TBODY><TR><TD><TABLE cellSpacing=10 cellPadding=0 width="100%"><TBODY><TR><TD colSpan=5><HR noShade SIZE=1></TD></TR><TR><TD vAlign=top align=left></TD><TD vAlign=bottom align=middle colSpan=2>Head
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Thorax and abdomen
<HR noShade SIZE=1></TD></TR><TR><TD vAlign=bottom align=left>dpi
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>GFP, %
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>IFA, %
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>pfu (log10)
<HR noShade SIZE=1></TD></TR><TR><TD vAlign=top align=left>3 </TD><TD vAlign=top align=middle>24 (12/50) </TD><TD vAlign=top align=middle>24 (12/50) </TD><TD vAlign=top align=middle>2.1 </TD></TR><TR><TD vAlign=top align=left>6 </TD><TD vAlign=top align=middle>33 (16/49) </TD><TD vAlign=top align=middle>30 (15/50) </TD><TD vAlign=top align=middle>1.7 </TD></TR><TR><TD vAlign=bottom align=left>9
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>52 (26/50)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>68 (34/50)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>2.3
<HR noShade SIZE=1></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
IFA, immunofluorescence assay.

sharon sanders · Aug 2, 2006

Figure 2

Figure 2

Fig. 2. eGFP expression at 3 dpi in mosquitoes coinjected with dsRNAs and ONNV-eGFP. (A) Coinjection of ONNV-eGFP and dsnsP3. (B) Coinjection of ONNV-eGFP and ds

$beta.gif$

gal. (C) Coinjection of ONNV-eGFP and dsAgAgo2. Mosquitoes injected with dsnsP3 show a dramatic reduction in eGFP expression when compared with ds

$beta.gif$

gal-injected controls, whereas mosquitoes injected with dsAgAgo2 show an increase in eGFP expression over controls.

sharon sanders · Aug 2, 2006

Table 3

Table 3

Table 3. Percentage of injected mosquitoes displaying eGFP expression in body tissues after coinjection of ONNV-eGFP and dsnsP3 or dsAgAgo2 at 3 and 6 dpi
<TABLE border=0><TBODY><TR><TD><TABLE cellSpacing=10 cellPadding=0 width="100%"><TBODY><TR><TD colSpan=11><HR noShade SIZE=1></TD></TR><TR><TD vAlign=top align=left></TD><TD vAlign=bottom align=middle colSpan=3>3 dpi
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle colSpan=3>6 dpi
<HR noShade SIZE=1></TD></TR><TR><TD vAlign=bottom align=left>Treatment
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Head
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Thorax
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Abdomen
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Head
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Thorax
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>Abdomen
<HR noShade SIZE=1></TD></TR><TR><TD vAlign=top align=left>ONNV-eGFP + no dsRNA </TD><TD vAlign=top align=left>10% (4/40) </TD><TD vAlign=top align=right>85% (34/40) </TD><TD vAlign=top align=middle>0% (0/40) </TD><TD vAlign=top align=right>36% (14/44) </TD><TD vAlign=top align=right>93% (41/44) </TD><TD vAlign=top align=middle>20% (9/44) </TD></TR><TR><TD vAlign=top align=left>ONNV-eGFP + ds

$beta.gif$

gal </TD><TD vAlign=top align=left>34% (20/58) </TD><TD vAlign=top align=right>86% (50/58) </TD><TD vAlign=top align=middle>34% (20/58) </TD><TD vAlign=top align=right>57% (30/53) </TD><TD vAlign=top align=right>89% (47/53) </TD><TD vAlign=top align=middle>57% (30/53) </TD></TR><TR><TD vAlign=top align=left>ONNV-eGFP + dsnsP3 </TD><TD vAlign=top align=left>23% (12/52) </TD><TD vAlign=top align=right>38% (20/52) </TD><TD vAlign=top align=middle>0% (0/52) </TD><TD vAlign=top align=right>36% (20/55) </TD><TD vAlign=top align=right>71% (39/55) </TD><TD vAlign=top align=middle>16% (9/55) </TD></TR><TR><TD vAlign=bottom align=left>ONNV-eGFP + dsAgAgo2
<HR noShade SIZE=1></TD><TD vAlign=bottom align=left>98% (62/63)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=right>100% (63/63)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>97% (61/63)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=right>100% (36/36)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=right>100% (36/36)
<HR noShade SIZE=1></TD><TD vAlign=bottom align=middle>100% (36/36)
<HR noShade SIZE=1></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>

sharon sanders · Aug 2, 2006

Figure 3

Figure 3

Fig. 3. Viral titers of ONNV-eGFP in mosquitoes coinjected with dsRNA homologous to ONNV nsP3 and AgAgo2. Compared with the nonspecific ds

$beta.gif$

gal, mosquitoes coinjected with virus and dsnsP3 had statistically significant decreases in infection at both 3 and 6 dpi (P < 0.0001). Viral titers of ONNV-eGFP increased significantly in mosquitoes at 3 and 6 dpi after coinjection with dsRNAs homologous with AgAgo2 (P < 0.0001 and P = 0.0006 at 3 and 6 dpi, respectively).

sharon sanders · Aug 2, 2006

Figure 5

Figure 5

Fig. 5. Viral titers of ONNV-eGFP in mosquitoes at 3 and 6 dpi after coinjection of dsRNA homologous to AgAgo1, AgAgo3, AgAgo4, and AgAgo5. Compared with the nonspecific ds

$beta.gif$

gal, only mosquitoes coinjected with virus and dsAgAgo3 had statistically significant increases at 3 and 6 dpi (P

$le.gif$

0.0141).

RNA interference as a natural antiviral to mosquito vectored diseases

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President

sharon sanders

Editor-in-Chief & President